Japan's Otsuka Offers New Hope in Fight Against Multi-drug resistant TB Multidrug resistant [MDR] TB accounts for more than 5 per cent of new cases of TB, which itself takes more than 2 million lives per year. Long-term progress in eliminating the disease depends on beating it back with a combination of new potent drugs and preventive public health measures. That drug option has lain basically dormant for more than 40 years – until now. Read more...
New Pharm Exec Video Round-Up Check out our new video program, Pharma 4: four minutes, four stories. This week: the Pharm Exec Top 50, risk monitoring and PPPs in Europe. More...
Merck Serono and Dr. Reddy's Team Up on Biosimilars Dr. Reddy’s Laboratories and Merck Serono have partnered to codevelop a portfolio of biosimilar compounds in oncology. The partnership will focus on monoclonal antibodies and covers co-development, manufacturing, and commercialization of the compounds worldwide. More...
Question Clinical Trial Enrolment 'Facts' Kenneth A. Getz reports on new Tufts' research that counters the previously held ‘fact’ that 20% of all investigative sites fail to enrol a single patient for clinical trials. More...
Recruitment Profile
Council of Europe
Scientific Programme Officer - OMCL Quality Assurance Programme (Grade A1/A2)
Duty station: Strasbourg (France)
Ref No: e146/2012 Read more
Product Profile
NNIT
GxP Cloud now with SaaS
With validated GxP applications ready as SaaS in NNIT's GxP Cloud you can save deployment and validation costs as well as time. Read more
Recruitment Profile
Council of Europe
Scientific Programme Officer - OMCL Quality Assurance Programme (Grade A1/A2)
Duty station: Strasbourg (France)
Ref No: e146/2012 Read more
